Lopinavir/ritonavir in new simplification strategies in antiretroviral therapy
Copyright © 2014 Elsevier España, S.L.U. All rights reserved..
Interest in simplification arises from the need to dispense with nucleoside analogs due to their long-term toxicity. Since the first trials analyzing the safety and effectiveness of the strategy with lopinavir/ritonavir (LPV/r) emerged more than 10 years ago, simplification continues to arouse scientific, clinical and economic interest. At present, there is no consensus on recommendations; interpretations of results are discordant: while some emphasize the greater risk of loss of virologic control, others indicate that the possible virological rebound with this strategy is unrelated to a loss of therapeutic options or to the emergence of resistance to ritonavir-boosted protease inhibitors. This scenario governs the recommendations that can be made in clinical practice; almost all groups agree that candidates should be selected for a simplification strategy with fewer drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 Suppl 3 |
|---|---|
| Enthalten in: |
Enfermedades infecciosas y microbiologia clinica - 32 Suppl 3(2014) vom: 15. Nov., Seite 12-7 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Lopinavir/ritonavir en nuevas estrategias de simplificación del tratamiento antirretroviral |
|---|
| Beteiligte Personen: |
Sebastián, María de Lagarde [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.10.2016 Date Revised 21.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/S0213-005X(14)70162-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM24490717X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM24490717X | ||
| 003 | DE-627 | ||
| 005 | 20231224135716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/S0213-005X(14)70162-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0816.xml |
| 035 | |a (DE-627)NLM24490717X | ||
| 035 | |a (NLM)25542870 | ||
| 035 | |a (PII)S0213-005X(14)70162-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Sebastián, María de Lagarde |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lopinavir/ritonavir in new simplification strategies in antiretroviral therapy |
| 246 | 3 | 3 | |a Lopinavir/ritonavir en nuevas estrategias de simplificación del tratamiento antirretroviral |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.10.2016 | ||
| 500 | |a Date Revised 21.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2014 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a Interest in simplification arises from the need to dispense with nucleoside analogs due to their long-term toxicity. Since the first trials analyzing the safety and effectiveness of the strategy with lopinavir/ritonavir (LPV/r) emerged more than 10 years ago, simplification continues to arouse scientific, clinical and economic interest. At present, there is no consensus on recommendations; interpretations of results are discordant: while some emphasize the greater risk of loss of virologic control, others indicate that the possible virological rebound with this strategy is unrelated to a loss of therapeutic options or to the emergence of resistance to ritonavir-boosted protease inhibitors. This scenario governs the recommendations that can be made in clinical practice; almost all groups agree that candidates should be selected for a simplification strategy with fewer drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Dual therapy | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Lopinavir/ritonavir | |
| 650 | 4 | |a Monoterapia | |
| 650 | 4 | |a Monotherapy | |
| 650 | 4 | |a Simplificación | |
| 650 | 4 | |a Simplification | |
| 650 | 4 | |a Terapia dual | |
| 650 | 4 | |a VIH | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a HIV Integrase Inhibitors |2 NLM | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Reverse Transcriptase Inhibitors |2 NLM | |
| 650 | 7 | |a lopinavir-ritonavir drug combination |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Pardo, Otilia Bisbal |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega, Federico Pulido |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Enfermedades infecciosas y microbiologia clinica |d 1993 |g 32 Suppl 3(2014) vom: 15. Nov., Seite 12-7 |w (DE-627)NLM01273425X |x 1578-1852 |7 nnns |
| 773 | 1 | 8 | |g volume:32 Suppl 3 |g year:2014 |g day:15 |g month:11 |g pages:12-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0213-005X(14)70162-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 Suppl 3 |j 2014 |b 15 |c 11 |h 12-7 | ||